International Journal of Hematology

, 82:243

Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Authors

  • Naoya Ochiai
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Noriko Yamada
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Ryo Uchida
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Shin-ichi Fuchida
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Akira Okano
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Mayumi Hatsuse
    • Shakaihoken Kyoto Hospital
  • Masashi Okamoto
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
  • Eishi Ashihara
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
    • Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of Medicine
Article

DOI: 10.1532/IJH97.05049

Cite this article as:
Ochiai, N., Yamada, N., Uchida, R. et al. Int J Hematol (2005) 82: 243. doi:10.1532/IJH97.05049

Abstract

The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma.

Key words

Multiple myelomaThalidomideIncadronateDexamethasone

Copyright information

© The Japanese Society of Hematology 2005